Corcept Therapeutics

This early-stage study is testing the safety and best dose of a new oral drug called nenocorilant when given alongside an established immunotherapy drug (nivolumab) for people with advanced solid tumors. The goal is to see if this combination can help control cancer growth. The s…

This study is testing whether adding an oral drug called relacorilant to two standard chemotherapy drugs can help control advanced pancreatic cancer that has spread. It will involve about 60 adults whose cancer has not yet been treated. The main goal is to see if this three-drug …

This study is testing whether an investigational drug called dazucorilant is safe and can help slow the progression of ALS (amyotrophic lateral sclerosis). It will involve about 279 adults with ALS across North America and Europe. The main goal is to see if the drug can help pati…

This early-stage study is testing whether a new drug called miricorilant can reduce fat buildup in the liver of people with MASH, a serious form of fatty liver disease. Eight participants will take the drug daily for six weeks while researchers measure changes in liver fat produc…

This study is testing whether adding an experimental drug called relacorilant to standard chemotherapy helps control advanced gynecologic cancers. It will enroll about 270 patients with ovarian, fallopian tube, peritoneal, or endometrial cancer that has returned or spread. The ma…